Plasma COVID-19 8mins Rapid Diagnostic Test Kit After Vaccination

Not all the antibodies are neutralizing. Non-neutralizing antibodies, or binding antibodies, are able to bind to viral antigens but do not block viral infection. Binding antibodies can flag the viral antigen to trigger immune responses but the presence of binding antibodies does not reflect the level of immunity. Neutralizing antibodies (NAbs) are antibodies that not only bind to viral antigens but also block viral infection. The presence of NAb can be used to evaluate immunity status after infection or vaccination.

Neutralizing Antibody Rapid Test Intended Use:

The 2019 novel coronavirus (SARS-CoV-2) has several structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N). The S-protein contains a receptor-binding domain (RBD), which can recognize the cell surface receptor, angiotensin-converting enzyme-2 (ACE2). In a recent study, neutralizing antibodies (NAb) can block the interaction between the receptor-binding domain (RBD) of the novel coronavirus spike protein with the ACE2 cell surface receptor. The level of NAb, therefore, can be used to analyze a patient’s immunity against future SARS-CoV-2 infection. This COVID-19 neutralizing antibody lateral flow assay rapidly detects any antibodies that can neutralize the RBD-ACE2 interaction.

Researchers have been using traditional viral neutralization assay for testing SARS-CoV-2 neutralizing antibodies and there are several ELISA based neutralizing antibody test kits available in the market since May 2020. However, performing COVID-19 neutralization assays or ELISA requires complex laboratory settings, and it is time-consuming, despite a higher sensitivity and specificity. JOYSBIO’s surrogate neutralizing antibody rapid test cassette provides an easy way for the preliminary screening of NAb to estimate patients’ immunity to novel coronavirus infection.  

Parameter: